[8-K] Monogram Technologies Inc. Reports Material Event
Monogram Technologies Inc. (MGRM) filed an 8-K on 30 Jul 2025 under Item 7.01 to furnish an email sent to shareholders.
The email directs investors to the FAQ section on the company鈥檚 Investor Relations website that addresses the previously announced Zimmer Biomet Holdings, Inc. acquisition (14 Jul 2025). No new financial statements, valuation metrics, or amended deal terms are included. The communication is provided as Exhibit 99.1 and, consistent with Reg FD, is treated as 鈥渇urnished,鈥� not 鈥渇iled,鈥� limiting Exchange Act liability.
Item 9.01 lists (i) Exhibit 99.1鈥擲hareholder Email and (ii) the Inline XBRL cover file. No other reportable events were disclosed.
Monogram Technologies Inc. (MGRM) ha presentato un modulo 8-K il 30 luglio 2025 ai sensi della voce 7.01 per fornire un'email inviata agli azionisti.
L'email indirizza gli investitori alla sezione FAQ del sito web delle Relazioni con gli Investitori della societ脿, che tratta dell'acquisizione precedentemente annunciata di Zimmer Biomet Holdings, Inc. (14 luglio 2025). Non sono inclusi nuovi bilanci, metriche di valutazione o termini modificati dell'accordo. La comunicazione 猫 fornita come Allegato 99.1 e, in conformit脿 con il Regolamento FD, 猫 considerata 鈥渇ornita鈥� e non 鈥渄epositata鈥�, limitando cos矛 la responsabilit脿 ai sensi dell'Exchange Act.
La voce 9.01 elenca (i) Allegato 99.1鈥擡mail agli Azionisti e (ii) il file di copertura Inline XBRL. Non sono stati divulgati altri eventi rilevanti.
Monogram Technologies Inc. (MGRM) present贸 un formulario 8-K el 30 julio 2025 bajo el punto 7.01 para proporcionar un correo electr贸nico enviado a los accionistas.
El correo electr贸nico dirige a los inversores a la secci贸n de preguntas frecuentes en el sitio web de Relaciones con Inversionistas de la compa帽铆a que aborda la adquisici贸n previamente anunciada de Zimmer Biomet Holdings, Inc. (14 julio 2025). No se incluyen nuevos estados financieros, m茅tricas de valoraci贸n ni t茅rminos modificados del acuerdo. La comunicaci贸n se proporciona como Anexo 99.1 y, conforme al Reglamento FD, se considera 鈥減roporcionada鈥� y no 鈥減resentada鈥�, limitando la responsabilidad bajo la Exchange Act.
El punto 9.01 enumera (i) Anexo 99.1鈥擟orreo Electr贸nico a Accionistas y (ii) el archivo de portada Inline XBRL. No se divulgaron otros eventos reportables.
Monogram Technologies Inc. (MGRM)電� 2025雲� 7鞗� 30鞚� 頃 7.01鞐� 霐半澕 欤检＜霌れ棎瓴� 氚滌啞霅� 鞚措⿺鞚检潉 鞝滉车頃橁赴 鞙勴暣 8-K 氤搓碃靹滊ゼ 鞝滌稖頄堨姷雼堧嫟.
鞚� 鞚措⿺鞚检潃 韴瀽鞛愲摛鞚� 須岇偓鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼 雮� FAQ 靹轨厴鞙茧 鞎堧偞頃橂┌, 鞚挫爠鞐� 氚滍憸霅� Zimmer Biomet Holdings, Inc. 鞚胳垬 瓯�(2025雲� 7鞗� 14鞚�)鞐� 雽�頃� 靹る獏頃橁碃 鞛堨姷雼堧嫟. 靸堧鞖� 鞛鞝滍憸, 韽夑皜 歆�響� 霕愲姅 靾橃爼霅� 瓯半灅 臁瓣贝鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟. 鞚� 旎る雼堨紑鞚挫厴鞚� 攵�靻嶌劀 99.1搿� 鞝滉车霅橂┌, Reg FD鞐� 霐半澕 鈥滌牅於滊惃(filed)鈥濎澊 鞎勲媽 鈥滌牅瓿惦惃(furnished)鈥濎溂搿� 觳橂Μ霅橃柎 Exchange Act鞐� 霐半ジ 毂呾瀯鞚� 鞝滍暅霅╇媹雼�.
頃 9.01鞐愲姅 (i) 攵�靻嶌劀 99.1鈥旍＜欤� 鞚措⿺鞚缄臣 (ii) 鞚鸽澕鞚� XBRL 旎る矂 韺岇澕鞚� 雮橃棿霅橃柎 鞛堨姷雼堧嫟. 雼るジ 氤搓碃 臧�電ロ暅 靷贝鞚� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.
Monogram Technologies Inc. (MGRM) a d茅pos茅 un formulaire 8-K le 30 juillet 2025 en vertu de l'article 7.01 pour fournir un courriel envoy茅 aux actionnaires.
Le courriel dirige les investisseurs vers la section FAQ du site web des Relations Investisseurs de la soci茅t茅, qui traite de l'acquisition pr茅c茅demment annonc茅e de Zimmer Biomet Holdings, Inc. (14 juillet 2025). Aucun nouvel 茅tat financier, indicateur d'茅valuation ou terme modifi茅 de l'accord n'est inclus. La communication est fournie en tant que 笔颈猫肠别&苍产蝉辫;99.1 et, conform茅ment au r猫glement FD, est consid茅r茅e comme 芦 fournie 禄 et non 芦 d茅pos茅e 禄, limitant la responsabilit茅 au titre de l'Exchange Act.
L'article 9.01 茅num猫re (i) la 笔颈猫肠别&苍产蝉辫;99.1鈥擟ourriel aux actionnaires et (ii) le fichier de couverture Inline XBRL. Aucun autre 茅v茅nement d茅clarable n'a 茅t茅 divulgu茅.
Monogram Technologies Inc. (MGRM) reichte am 30. Juli 2025 ein Formular 8-K unter Punkt 7.01 ein, um eine an Aktion盲re gesendete E-Mail bereitzustellen.
Die E-Mail verweist Investoren auf den FAQ-Bereich der Investor-Relations-Website des Unternehmens, der die zuvor angek眉ndigte 脺bernahme von Zimmer Biomet Holdings, Inc. (14. Juli 2025) behandelt. Es sind keine neuen Finanzberichte, Bewertungskennzahlen oder ge盲nderten Vertragsbedingungen enthalten. Die Mitteilung wird als Anlage 99.1 bereitgestellt und gem盲脽 Reg FD als 鈥瀊ereitgestellt鈥� und nicht 鈥瀍ingereicht鈥� behandelt, was die Haftung nach dem Exchange Act begrenzt.
Punkt 9.01 listet (i) Anlage 99.1鈥擜ktion盲rs-E-Mail und (ii) die Inline-XBRL-Coverdatei auf. Weitere meldepflichtige Ereignisse wurden nicht offengelegt.
- None.
- None.
Insights
TL;DR: Routine 8-K furnishes shareholder email; no new Zimmer Biomet deal terms; transparency up, valuation unchanged.
The filing merely forwards an email steering investors to existing FAQs about the previously announced Zimmer Biomet takeover. Because it offers no fresh financial data or revised consideration, the market鈥檚 assessment of the deal鈥檚 value remains unchanged. The exhibit鈥檚 furnished status shields Monogram from Exchange Act liability while satisfying Reg FD. Overall impact on merger probability, timing, or pricing is neutral.
TL;DR: Disclosure complies with Reg FD, keeps investors informed, free of litigation risk; governance-neutral.
By publicly furnishing the same information provided to shareholders, Monogram mitigates selective-disclosure risk. However, because the email simply points to already-public FAQs, the governance benefit is marginal. No board or executive changes, voting recommendations, or regulatory actions are reported, resulting in a neutral governance impact.
Monogram Technologies Inc. (MGRM) ha presentato un modulo 8-K il 30 luglio 2025 ai sensi della voce 7.01 per fornire un'email inviata agli azionisti.
L'email indirizza gli investitori alla sezione FAQ del sito web delle Relazioni con gli Investitori della societ脿, che tratta dell'acquisizione precedentemente annunciata di Zimmer Biomet Holdings, Inc. (14 luglio 2025). Non sono inclusi nuovi bilanci, metriche di valutazione o termini modificati dell'accordo. La comunicazione 猫 fornita come Allegato 99.1 e, in conformit脿 con il Regolamento FD, 猫 considerata 鈥渇ornita鈥� e non 鈥渄epositata鈥�, limitando cos矛 la responsabilit脿 ai sensi dell'Exchange Act.
La voce 9.01 elenca (i) Allegato 99.1鈥擡mail agli Azionisti e (ii) il file di copertura Inline XBRL. Non sono stati divulgati altri eventi rilevanti.
Monogram Technologies Inc. (MGRM) present贸 un formulario 8-K el 30 julio 2025 bajo el punto 7.01 para proporcionar un correo electr贸nico enviado a los accionistas.
El correo electr贸nico dirige a los inversores a la secci贸n de preguntas frecuentes en el sitio web de Relaciones con Inversionistas de la compa帽铆a que aborda la adquisici贸n previamente anunciada de Zimmer Biomet Holdings, Inc. (14 julio 2025). No se incluyen nuevos estados financieros, m茅tricas de valoraci贸n ni t茅rminos modificados del acuerdo. La comunicaci贸n se proporciona como Anexo 99.1 y, conforme al Reglamento FD, se considera 鈥減roporcionada鈥� y no 鈥減resentada鈥�, limitando la responsabilidad bajo la Exchange Act.
El punto 9.01 enumera (i) Anexo 99.1鈥擟orreo Electr贸nico a Accionistas y (ii) el archivo de portada Inline XBRL. No se divulgaron otros eventos reportables.
Monogram Technologies Inc. (MGRM)電� 2025雲� 7鞗� 30鞚� 頃 7.01鞐� 霐半澕 欤检＜霌れ棎瓴� 氚滌啞霅� 鞚措⿺鞚检潉 鞝滉车頃橁赴 鞙勴暣 8-K 氤搓碃靹滊ゼ 鞝滌稖頄堨姷雼堧嫟.
鞚� 鞚措⿺鞚检潃 韴瀽鞛愲摛鞚� 須岇偓鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼 雮� FAQ 靹轨厴鞙茧 鞎堧偞頃橂┌, 鞚挫爠鞐� 氚滍憸霅� Zimmer Biomet Holdings, Inc. 鞚胳垬 瓯�(2025雲� 7鞗� 14鞚�)鞐� 雽�頃� 靹る獏頃橁碃 鞛堨姷雼堧嫟. 靸堧鞖� 鞛鞝滍憸, 韽夑皜 歆�響� 霕愲姅 靾橃爼霅� 瓯半灅 臁瓣贝鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟. 鞚� 旎る雼堨紑鞚挫厴鞚� 攵�靻嶌劀 99.1搿� 鞝滉车霅橂┌, Reg FD鞐� 霐半澕 鈥滌牅於滊惃(filed)鈥濎澊 鞎勲媽 鈥滌牅瓿惦惃(furnished)鈥濎溂搿� 觳橂Μ霅橃柎 Exchange Act鞐� 霐半ジ 毂呾瀯鞚� 鞝滍暅霅╇媹雼�.
頃 9.01鞐愲姅 (i) 攵�靻嶌劀 99.1鈥旍＜欤� 鞚措⿺鞚缄臣 (ii) 鞚鸽澕鞚� XBRL 旎る矂 韺岇澕鞚� 雮橃棿霅橃柎 鞛堨姷雼堧嫟. 雼るジ 氤搓碃 臧�電ロ暅 靷贝鞚� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.
Monogram Technologies Inc. (MGRM) a d茅pos茅 un formulaire 8-K le 30 juillet 2025 en vertu de l'article 7.01 pour fournir un courriel envoy茅 aux actionnaires.
Le courriel dirige les investisseurs vers la section FAQ du site web des Relations Investisseurs de la soci茅t茅, qui traite de l'acquisition pr茅c茅demment annonc茅e de Zimmer Biomet Holdings, Inc. (14 juillet 2025). Aucun nouvel 茅tat financier, indicateur d'茅valuation ou terme modifi茅 de l'accord n'est inclus. La communication est fournie en tant que 笔颈猫肠别&苍产蝉辫;99.1 et, conform茅ment au r猫glement FD, est consid茅r茅e comme 芦 fournie 禄 et non 芦 d茅pos茅e 禄, limitant la responsabilit茅 au titre de l'Exchange Act.
L'article 9.01 茅num猫re (i) la 笔颈猫肠别&苍产蝉辫;99.1鈥擟ourriel aux actionnaires et (ii) le fichier de couverture Inline XBRL. Aucun autre 茅v茅nement d茅clarable n'a 茅t茅 divulgu茅.
Monogram Technologies Inc. (MGRM) reichte am 30. Juli 2025 ein Formular 8-K unter Punkt 7.01 ein, um eine an Aktion盲re gesendete E-Mail bereitzustellen.
Die E-Mail verweist Investoren auf den FAQ-Bereich der Investor-Relations-Website des Unternehmens, der die zuvor angek眉ndigte 脺bernahme von Zimmer Biomet Holdings, Inc. (14. Juli 2025) behandelt. Es sind keine neuen Finanzberichte, Bewertungskennzahlen oder ge盲nderten Vertragsbedingungen enthalten. Die Mitteilung wird als Anlage 99.1 bereitgestellt und gem盲脽 Reg FD als 鈥瀊ereitgestellt鈥� und nicht 鈥瀍ingereicht鈥� behandelt, was die Haftung nach dem Exchange Act begrenzt.
Punkt 9.01 listet (i) Anlage 99.1鈥擜ktion盲rs-E-Mail und (ii) die Inline-XBRL-Coverdatei auf. Weitere meldepflichtige Ereignisse wurden nicht offengelegt.
FAQ
What triggered Monogram Technologies' (MGRM) 8-K filing on July 30, 2025?
Does the 8-K provide new financial terms for the Zimmer Biomet deal?
Where can MGRM investors find the FAQs mentioned in the filing?
Are any financial statements or pro-forma data included in this report?
Is Exhibit 99.1 considered filed or furnished?
What exchange and ticker symbol does Monogram Technologies use?
